The Prognostic Value of Expression of the Long Noncoding RNA (lncRNA) Small Nucleolar RNA Host Gene 1 (SNHG1) in Patients with Solid Malignant Tumors: A Systematic Review and Meta-Analysis.
The Prognostic Value of Expression of the Long Noncoding RNA (lncRNA) Small Nucleolar RNA Host Gene 1 (SNHG1) in Patients with Solid Malignant Tumors: A Systematic Review and Meta-Analysis.
复制标题
长非编码 RNA (lncRNA) 小核仁 RNA 宿主基因 1 (SNHG1) 在实体恶性肿瘤患者中表达的预后价值：系统评价和荟萃分析
DOI：
10.12659/msm.911687
复制
发表时间：
2018-08-06
期刊：
影响因子：
--
通讯作者：
Yu B
中科院分区：
文献类型：
--
作者：
Xiao B;Huang Z;Zhou R;Zhang J;Yu B
背景长非编码RNA（lncRNA）小核仁RNA宿主基因1（SNHG1）在实体恶性肿瘤中表达。本系统评价和荟萃分析的目的是确定 lncRNA SNHG1 的表达是否与恶性肿瘤患者的预后相关。材料/方法 1970 年 1 月至 2018 年 7 月的文献综述确定了英语出版物。检索的数据库包括：PubMed、OVID、Web of Science、Cochrane 数据库、Embase、EBSCO、Google Scholar。系统评价和荟萃分析是根据系统评价和荟萃分析的首选报告项目（PRISMA）指南进行的。使用纽卡斯尔-渥太华量表（NOS）评估偏倚风险的工具。结果 共鉴定出 8 篇出版物（570 名患者）和 8 种实体瘤，包括骨肉瘤、结直肠癌、肝细胞癌、非小细胞肺癌、食管癌、卵巢癌、神经胶质瘤和胃癌。 Meta 分析显示，lncRNA SNHG1 的表达与总生存期 (OS) 降低显着相关（HR=1.917；95% CI，1.58–2.31）（P<0.001）。亚组分析显示，lncRNA SNHG1表达与TNM分期（OR=3.99；95% CI，2.48-6.43）和淋巴结转移（OR=3.12；95% CI，1.95-4.98）显着相关。 lncRNA SNHG1 表达与患者性别、肿瘤亚型或肿瘤大小之间没有显着相关性。结论 系统文献回顾和荟萃分析确定了 8 篇出版物，包括 570 名患有 8 种类型实体恶性肿瘤的患者，并表明 lncRNA SNHG1 的表达与较差的临床结果显着相关。
Background The long non-coding RNA (lncRNA) small nucleolar RNA host gene 1 (SNHG1) is expressed in solid malignant tumors. The aim of this systematic review and meta-analysis was to determine whether expression of the lncRNA SNHG1 was associated with prognosis in patients with malignancy. Material/Methods A literature review from Jan 1970 to July 2018 identified publications in the English language. Databases searched included: PubMed, OVID, Web of Science, the Cochrane Database, Embase, EBSCO, Google Scholar. Systematic review and meta-analysis were performed according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. The Newcastle-Ottawa Scale (NOS) assessment tool for risk of bias was used. Results Eight publications (570 patients) and eight solid tumors were identified, including osteosarcoma, colorectal cancer, hepatocellular carcinoma, non-small cell lung cancer, esophageal cancer, ovarian cancer, glioma, and gastric cancer. Meta-analysis showed that expression of the lncRNA SNHG1 was significantly correlated with reduced overall survival (OS) (HR=1.917; 95% CI, 1.58–2.31) (P<0.001). Subgroup analysis showed that lncRNA SNHG1 expression was significantly correlated with TNM stage (OR=3.99; 95% CI, 2.48–6.43) and lymph node metastasis (OR=3.12; 95% CI, 1.95–4.98). There were no significant correlations between lncRNA SNHG1 expression and patient gender, tumor subtype, or tumor size. Conclusions Systematic literature review and meta-analysis identified eight publications that included 570 patients with eight types of solid malignant tumor, and showed that the expression of the lncRNA SNHG1 was significantly associated with worse clinical outcome.